



Supplemental Figure 5: Impact of MYC SV on OS and PFS in hyperdiploid and non-hyperdiploid groups. Comparison of OS (years) in patients with a MYC SV (blue line), and no MYC abnormality (red line) from the CoMMpass cohort in the hyperdiploid group in **A** or in the non-hyperdiploid group in **B**. In the hyperdiploid group, OS time (mean) was 5.9 years [95%CI:5.5-6.4] and 5.0 years [95%CI:4.5-5.5] in MYC SV (n=162) and no MYC SV (n=135) cohorts, respectively. In the non-hyperdiploid group, OS time (mean) was 5.1 years [95%CI:4.4-5.9] and 5.6 years [95%CI:5.2-6.1] in MYC SV (n=63), and no MYC SV (n=185) cohorts, respectively. Comparison of OS (years) in patients with no MYC abnormality (green line), and no MYC SV (blue line) in **C**. OS time (mean) was 5.5 years [95%CI:5.2-5.9] in the no MYC abnormality (n=320) and 5.6 years [95%CI:5.2-6.0] in no MYC SV (n=281). Comparison of PFS (years) in patients with a MYC expression SV (blue line), and no MYC abnormality (red line) from the CoMMpass cohort in the hyperdiploid group in **D** or in the non-hyperdiploid group in **E**. In the hyperdiploid group, PFS time (median) was 3.5 years [95%CI:2.9-4.1] and 3.0 years [95%CI:2.3-3.7] in MYC SV (n=161), and no MYC SV (n=134) cohorts, respectively. In the non-hyperdiploid group, PFS time (median) was 2.5 years [95%CI:1.8-3.1] and 3.3 years [95%CI:2.2-4.3] in MYC SV (n=63), and no MYC SV (n=184) cohorts, respectively. Comparison of PFS (years) in patients with no MYC abnormality (green line), and no MYC SV (blue line) in **F**. PFS time (median) was 3.2 years [95%CI:2.4-3.9] in the no MYC abnormality (N=318) and 3.1 years [95%CI:2.4-3.9] in no MYC SV (n=279).